在标准和酸性条件下，新型 pH 激活氟喹诺酮类药物法氟沙星的体外活性谱。
In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.
机构信息
MerLion Pharmaceuticals GmbH, Robert-Rössle Strasse 10, Berlin, Germany.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4394-7. doi: 10.1128/AAC.00833-10. Epub 2011 Jun 27.
Abstract
Finafloxacin is a novel fluoroquinolone that exhibits enhanced antibacterial activity under acidic conditions. The aim of this study was to define the in vitro pH-activity relationship. Finafloxacin exhibited optimal antibacterial activity between pH 5.0 and 6.0 at which MICs were 4- to 8-fold lower than those determined at neutral pH. These observations were then confirmed against a larger collection of bacteria. These data suggest that finafloxacin could potentially offer a therapeutic advantage within acidic foci of infection.
摘要
菲那沙星是一种新型氟喹诺酮类药物，在酸性条件下表现出增强的抗菌活性。本研究旨在确定体外 pH-活性关系。菲那沙星在 pH5.0 到 6.0 之间表现出最佳的抗菌活性，此时 MIC 比在中性 pH 时低 4 到 8 倍。这些观察结果随后在更大的细菌集合中得到了证实。这些数据表明，菲那沙星在感染的酸性病灶内可能具有潜在的治疗优势。
相似文献
1
In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.
Antimicrob Agents Chemother. 2011 Sep;55(9):4394-7. doi: 10.1128/AAC.00833-10. Epub 2011 Jun 27.
2
Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.
Int J Antimicrob Agents. 2011 Jul;38(1):52-9. doi: 10.1016/j.ijantimicag.2011.03.002. Epub 2011 May 18.
3
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
Antimicrob Agents Chemother. 2010 Apr;54(4):1613-5. doi: 10.1128/AAC.01637-09. Epub 2010 Jan 25.
4
Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00082-17. Print 2017 Jul.
5
Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.
J Antimicrob Chemother. 2011 Dec;66(12):2809-13. doi: 10.1093/jac/dkr393. Epub 2011 Sep 21.
6
Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.
J Urol. 2015 Aug;194(2):563-70. doi: 10.1016/j.juro.2015.01.094. Epub 2015 Jan 29.
7
Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.
J Antimicrob Chemother. 2010 Dec;65(12):2530-3. doi: 10.1093/jac/dkq375. Epub 2010 Oct 12.
8
Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes.
Clin Microbiol Infect. 2020 Sep;26(9):1254.e1-1254.e8. doi: 10.1016/j.cmi.2019.07.028. Epub 2019 Aug 9.
9
10
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2006 Jun;50(6):2106-12. doi: 10.1128/AAC.01359-05.
引用本文的文献
1
An evaluation of antibiotic options for the treatment of biothreat pathogens.
Front Antibiot. 2025 Aug 14;4:1611588. doi: 10.3389/frabi.2025.1611588. eCollection 2025.
2
liver abscesses: pathogenesis, treatment, and ongoing challenges.
Infect Immun. 2025 Aug 12;93(8):e0050824. doi: 10.1128/iai.00508-24. Epub 2025 Jul 3.
3
Layering vaccination with antibiotic therapy results in protection and clearance of in Balb/c mice.
Infect Immun. 2024 Mar 12;92(3):e0045523. doi: 10.1128/iai.00455-23. Epub 2024 Jan 30.
4
Exploitation of microbial activities at low pH to enhance planetary health.
FEMS Microbiol Rev. 2024 Jan 12;48(1). doi: 10.1093/femsre/fuad062.
5
Comparison of the antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against strains isolated in China.
Heliyon. 2023 Oct 30;9(11):e21216. doi: 10.1016/j.heliyon.2023.e21216. eCollection 2023 Nov.
6
Activity of Finafloxacin against Panels of Respiratory Pathogens.
Antibiotics (Basel). 2023 Jun 23;12(7):1096. doi: 10.3390/antibiotics12071096.
7
A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.
Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.
8
Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.
EMBO Rep. 2023 Jan 9;24(1):e56033. doi: 10.15252/embr.202256033. Epub 2022 Dec 19.
9
Efficacy of finafloxacin in a murine model of inhalational glanders.
Front Microbiol. 2022 Nov 24;13:1057202. doi: 10.3389/fmicb.2022.1057202. eCollection 2022.
10
An Investigation into the Re-Emergence of Disease Following Cessation of Antibiotic Treatment in Balb/c Mice Infected with Inhalational .
Antibiotics (Basel). 2022 Oct 20;11(10):1442. doi: 10.3390/antibiotics11101442.
本文引用的文献
1
Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine.
Antimicrob Agents Chemother. 2011 Apr;55(4):1814-8. doi: 10.1128/AAC.00886-10. Epub 2011 Jan 18.
2
Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.
J Antimicrob Chemother. 2010 Dec;65(12):2530-3. doi: 10.1093/jac/dkq375. Epub 2010 Oct 12.
3
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
Antimicrob Agents Chemother. 2010 Apr;54(4):1613-5. doi: 10.1128/AAC.01637-09. Epub 2010 Jan 25.
4
Hyperinflammation in airways of cystic fibrosis patients: what's new?
Expert Rev Mol Diagn. 2008 Jul;8(4):359-63. doi: 10.1586/14737159.8.4.359.
5
Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide.
Infection. 2005 Dec;33 Suppl 2:36-43. doi: 10.1007/s15010-005-8206-y.
6
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.
J Clin Invest. 2006 Feb;116(2):436-46. doi: 10.1172/JCI24684. Epub 2006 Jan 26.
7
Antimicrobial safety: focus on fluoroquinolones.
Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57. doi: 10.1086/428055.
8
Conditions affecting the results of susceptibility testing for the quinolone compounds.
Chemotherapy. 1988;34(4):308-14. doi: 10.1159/000238584.
Zotero 插件